- Home
- PRAX vs FOR Comparison
PRAX vs FOR Comparison
Compare PRAX & FOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- FOR
- Stock Information
- Founded
- PRAX 2015
- FOR 2005
- Country
- PRAX United States
- FOR United States
- Employees
- PRAX N/A
- FOR N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- FOR Real Estate
- Sector
- PRAX Health Care
- FOR Finance
- Exchange
- PRAX Nasdaq
- FOR Nasdaq
- Market Cap
- PRAX 950.8M
- FOR 1.0B
- IPO Year
- PRAX 2020
- FOR 2007
- Fundamental
- Price
- PRAX $47.08
- FOR $27.02
- Analyst Decision
- PRAX Strong Buy
- FOR Strong Buy
- Analyst Count
- PRAX 10
- FOR 4
- Target Price
- PRAX $102.00
- FOR $30.25
- AVG Volume (30 Days)
- PRAX 578.2K
- FOR 222.8K
- Earning Date
- PRAX 08-04-2025
- FOR 07-22-2025
- Dividend Yield
- PRAX N/A
- FOR N/A
- EPS Growth
- PRAX N/A
- FOR N/A
- EPS
- PRAX N/A
- FOR 3.19
- Revenue
- PRAX $7,765,000.00
- FOR $1,543,300,000.00
- Revenue This Year
- PRAX N/A
- FOR $4.28
- Revenue Next Year
- PRAX $3,567.38
- FOR $7.75
- P/E Ratio
- PRAX N/A
- FOR $8.48
- Revenue Growth
- PRAX 338.45
- FOR 2.35
- 52 Week Low
- PRAX $26.70
- FOR $18.00
- 52 Week High
- PRAX $91.83
- FOR $34.82
- Technical
- Relative Strength Index (RSI)
- PRAX 42.83
- FOR 70.97
- Support Level
- PRAX $44.25
- FOR $25.41
- Resistance Level
- PRAX $49.97
- FOR $26.69
- Average True Range (ATR)
- PRAX 3.36
- FOR 0.69
- MACD
- PRAX -0.89
- FOR 0.04
- Stochastic Oscillator
- PRAX 18.84
- FOR 79.62
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.